Johnson & Johnson reported strong quarterly earnings, boosted by surging sales of a new drug for hepatitis C that are expected to evaporate in coming months due to competition from a more potent and convenient combination treatment.
After the earnings announcement, the company's shares rose in premarket trading. (Get the latest quote here.)
The diversified health-care company on Tuesday said it earned $4.75 billion, or $1.66 per share, in the third quarter. That compared with $2.98 billion, or $1.04 per share, in the year-earlier period, when J&J took special charges related to legal expenses and merger-related costs.
Company sales rose 5.1 percent to $18.47 billion, topping the average analyst estimate of $18.38 billion compiled by Thomson Reuters I/B/E/S.
The company posted third-quarter earnings excluding items of $1.50 per share, up from $1.36 a share in the year-earlier period.
Analysts had expected J&J to report earnings excluding items of $1.44 a share, according to a consensus estimate from Thomson Reuters.